This article is an interview with Jim Wilson, a professor at the University of Pennsylvania and a pioneer in gene therapy. Wilson discusses the current state of gene therapy, including the FDA approval of the first CRISPR-based cell therapy for sickle cell disease. He also addresses the high prices of these treatments and the challenges of global access. Wilson mentions progress in in vivo editing of bone marrow stem cells and the potential for future advancements in gene therapy. He concludes by discussing the financing climate for gene therapy startups and the challenges they face in developing viable business models. The article highlights challenges and developments in the field of gene therapy, including market segmentation and inefficient use of capital. It emphasizes the importance of planning for commercialization and global access, as well as collaboration among stakeholders. The article also mentions trends in delivery systems and efforts to improve safety in gene therapy. The author expresses optimism about the future of gene therapy, with the potential for solutions to genetic diseases and early intervention through genome sequencing and newborn screening. [Extracted from the article]